49results about How to "Enhance anti-cancer efficacy" patented technology

The present invention provides a composition comprising a nicotine-containing material and an anti-cancer agent usable in the treatment and / or prevention or reduction of the risk of cancer and precancerous conditions as well as for preventing or reducing the risk of cancer recurrence. Furthermore, a composition comprising a nicotine-containing material and an anti-inflammatory agent usable in the treatment and / or prevention or reduction of the risk of inflammation, is provided. The nicotine containing composition can also include both an anti-cancer agent and an anti-inflammatory agent A device for administering the composition of the present invention to subjects can be a cigarette, smoking pipe, smokeless tobacco, electronic cigarette, transdermal patch or the like.

The present invention relates to a polymer nanoparticle injection formulation composition containing rapamycin with improved water solubility, and more specifically, to an injection formulation composition containing rapamycin wherein water solubility is improved by solubilizing rapamycin having low water solubility with polymer nanoparticles, a preparation method thereof, and an anticancer composition for a combined use with radiotherapy.

The present invention provides a pegylated lapatinib, an injection and a preparation method thereof, wherein the general formula of the pegylated lapatinib is defined in the specification, A is selected from a single-arm or multi-arm polyethylene glycol or poly ethylene glycol derivative, X is selected from the formula defined in the specification, Y and M are independently and respectively selected from double carboxylic acids having amino or corresponding acyl substituents, N is selected from an amino acid or peptide, LPT is lapatinib, a is 0 or 1, b is 0 or 1, c is 1 or 2, d is 1 or 2, and e is equal to the arm number of X. According to the present invention, the pegylated drug of lapatinib is synthesized, such that the lapatinib toxicity is reduced, the water solubility and the biological stability are improved, the drug resistance of cancer cells and cancer stem cells are avoided, the targeting property is enhanced, and the anticancer treatment effect is significantly improved.

Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble chelator, polyethylene glycol or polymer such as poly (1-glutamic acid) or poly (1-aspartic acid). Also disclosed are methods of using the compositions for treatment of tumors, autoimmune disorders such as rheumatoid arthritis and for prediction of paclitaxel uptake by tumors and radiolabeled DTPA-paclitaxel tumor imaging. Other embodiments include the coating of implantable stents for prevention of restenosis.

The present invention provides a pegylated lapatinib, an injection and a preparation method thereof, wherein the general formula of the pegylated lapatinib is defined in the specification, A is selected from a single-arm or multi-arm polyethylene glycol or poly ethylene glycol derivative, X is selected from the formula defined in the specification, Y and M are independently and respectively selected from double carboxylic acids having amino or corresponding acyl substituents, N is selected from an amino acid or peptide, LPT is lapatinib, a is 0 or 1, b is 0 or 1, c is 1 or 2, d is 1 or 2, and e is equal to the arm number of X. According to the present invention, the pegylated drug of lapatinib is synthesized, such that the lapatinib toxicity is reduced, the water solubility and the biological stability are improved, the drug resistance of cancer cells and cancer stem cells are avoided, the targeting property is enhanced, and the anticancer treatment effect is significantly improved.

The invention relates to a medicine composition for treating breast cancer. Various natural Chinese herbs are adopted as raw materials. In the raw material components, radix codonopsis and bighead atractylodes rhizomes have the effect of improving the immunity of the human body, radix astragali has the effects of tonifying qi and the spleen, and inducing diuresis to alleviate edema, radix angelica sinensis, tubers of scirpus yagara ohw, curcuma phaeocaulis valeton, winged euonymus twigs and rhizoma corydalis have the effect of activating blood circulation to dissipate stasis, and radix actinidiae chinensis, spreading hedyotis herb, Chinese lobelia herb, lalang grass rhizomes, black nightshade herb, solanum lyratum thunb, herba rabdosiae rubescentis and coix seeds have the effect of clearing away heat and toxic materials, and have the effects of calming endogenous wind and relieving phlegm, clearing and activating the channels and collaterals, and counteracting toxic substances and removing stasis with the assistance of scorpions; all the medicine materials are in coordinate compatibility, mutually supplement one another, jointly achieve the effects of suppressing tumors and removing stasis, activating blood circulation to dissipate stasis, and activating meridians to stop pain, and are remarkable in treatment effect on breast cancer and capable of treating both the symptoms and root causes; besides, the medicine composition is a pure traditional Chinese preparation, is free of toxic or side effects, and improves the constitution of a patient, improves the immunity and relieves toxicity while inhibiting the growth and transfer of cancer cells, and thus the anti-cancer treatment effect is enhanced.

The present invention is directed to particular antibodies and fragments thereof that find use in the detection, prevention and treatment of diseases and disorders associated with abnormal angiogenesis. In particular, these antibodies detect tumor endothelial marker 8 (TEM8) in its native and cell-surface expressed form. Also disclosed are improved methods for producing monoclonal antibodies, as well as pharmaceutical compositions and kits.

Theranostic agents useful for imaging and treating metastatic cancer are provided. The theranostic agents comprise a TMTP1 peptide conjugated to an albumin binding moiety to prolong circulation lifetime and a chelating agent to allow complexation of a diagnostic metal ion with the theranostic agent. The theranostic agent can be conjugated, for example, to a positron-emitting metal radionuclide suitable for PET imaging such as 64Cu, 68Ga, 44Sc, 86Y, 89Zr, or 82Rb; or a gamma-emitting metal radionuclide suitable for single photon emission computed tomography (SPECT) imaging such as 67Ga, 99mTc, 111In, or 177Lu. Alternatively, theranostic agents can be conjugated with a paramagnetic metal ion suitable for use in magnetic resonance imaging (MRI) such as manganese (e.g., Mn2+), iron (e.g., Fe3+, Fe2+) or gadolinium (e.g., Gd3+). Such theranostic agents show selective uptake by metastatic cancer cells and are useful for PET, SPECT, or MRI imaging of metastatic cells in vitro and in vivo.

A preparation method of javanica javanica oil emulsion injection, the javanica javanica oil emulsion injection contains 5-20g of pure javanica javanica oil per 100ml emulsion, 0.75-2.5g of a medicinally acceptable emulsifier, and an isotonic dose of medicine With an acceptable isotonic agent, the balance is water. The main preparation feature is to dissolve the oil phase components and the water phase separately, prevent the generation of impurities as much as possible during the preparation process, emulsify at a certain temperature to make colostrum, and then homogenize until the particle size of the emulsion reaches 50-300nm. Brucea Brucea Oil Emulsion Injection prepared by this method is being declared as a new drug under the trade name of An Ti Kang Injection. This Brucea Brucea Oil Emulsion Injection can ensure that the preparation can be directly injected intravenously, and improve the safe dosage of the drug, giving full play to the injection. The directional distribution of the emulsion and the directional effect of the lymphatic system are used to fully exert its therapeutic effect on cancer.

A protein nanocage formulation with enhanced mucus penetration capability and colloidal stability provides controlled delivery of therapeutic, prophylactic, or diagnostic agents to tumors. A dense coating of a surface altering agent such as polyethylene glycol on self-assembled protein nanocages enhances the rapid and uniform distribution of the formulation at mucosal tissues following topical administration, enhances circulation time following intravenous administration, and enhances penetration into hypoxic tumor cores. The density and the molecular weight of surface altering agents are selected to allow the protein nanocages to also bind to tumor cell receptors and release chemotherapeutic agents after tumor cell uptake. Agents delivered in the formulation have better efficacy compared to carrier-free agents. A method of making the protein nanocage formulation with enhanced mucus penetration and colloidal stability is also provided.

A method for expanding a population of γδ T-cells is provided in which isolated activated Peripheral Blood Mononuclear Cells (PBMCs) are cultured in a medium comprising transforming growth factor beta (TGF-β) under conditions in which the production of effector γδ T-cells having therapeutic activity against malignant disease is favored. The use of TGF-β in the production of effector cells in particular Vγ9Vδ2 T-cells is also described and claimed.

The present invention provides a humanized monoclonal antibody against extracellular domain of human death receptor 5, comprising a light chain variable region, whose amino acid sequence has at least 90% identity with the amino acid sequence shown as SEQ ID NO: 1, a heavy chain variable region, whose amino acid sequence has at least 90% identity with the amino acid sequence shown as SEQ ID NO: 2, and constant region derived from human antibody. The present invention also provides nucleotide sequence encoding said humanized monoclonal antibody, a recombinant eukaryotic expression vector, a process for preparing the humanized monoclonal antibody, and the composition and use therefore. Said humanized monoclonal antibody of the present invention shows specific apoptosis-inducing activity against various cancer cells both in vivo and in vitro, and thus it can be used alone or in combination with natural ligand of DR5, apoptosis-inducing ligand associated with tumor nerosis factor or other medicaments for the treatment of a variety of cancers as well as other diseases associated with high DR5 expression.

The invention discloses a tumor vaccine combined with oncolytic virus and neoantigen and its preparation method. The combined vaccine can be realized in two ways. The efficiency of reagents being phagocytized by antigen-presenting cells and increasing the number of T cells that can specifically recognize tumor neoantigens and tumor infiltration ability, thereby enhancing the anticancer effect; the second is to insert genes encoding tumor neoantigens into oncolytic virus vectors Among them, a large number of tumor neoantigens are expressed, combined with the tumor killing ability of oncolytic viruses, further enhance the local immune response of tumor lesions, increase the infiltration degree of killer T cells in tumor tissues, and cause local immunogenic responses and stimulate effects. The generation of cells achieves the anti-cancer effect; through experimental comparison, it is found that both the first combination vaccine and the second combination vaccine have good tumor-inhibiting effects, and the second combination vaccine has a significant tumor-inhibiting effect.

The invention discloses an isosorbide mononitrate derivative, a preparation method thereof and an application thereof to tumor combined treatment as shown in the formula (II). Ester is formed by isosorbide mononitrate and fatty acid through an esterification reaction, so that lipid solubility can be improved, and then a lipid nanoparticle passive targeting drug delivery system is further prepared. Afterwards, the drug combination is conducted by lipid nanoparticles of an isosorbide mononitrate fatty acid derivative and nano targeting anticancer drugs, and the therapeutic effect of chemotherapeutic drugs is improved.

A composite antisense nucleic acid medicine able to suppress the function of bcr3 / abl2 and VEGF genes features that the fusion gene bcr / abl and the vascular endothelial growth factor (VEGF) are its target and the antisense oligonucleotides (AS-ODNs) of said genes are acting on K562 cell line and k562 transfer tumor. It can be used to prepare the medicine for the pharmacotherapy and gene therapy of chronic granulocyte leukemia, and increasing the sensitivity of leukemia cells to chemicotherapeutic medicine.